Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.

Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME.

Acta Neuropathol. 2012 Oct;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub 2012 Jul 19. Erratum in: Acta Neuropathol. 2013 Jul;126(1):159.

2.

DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Bady P, Diserens AC, Castella V, Kalt S, Heinimann K, Hamou MF, Delorenzi M, Hegi ME.

Neuro Oncol. 2012 Jun;14(6):701-11. doi: 10.1093/neuonc/nos072. Epub 2012 May 8.

3.

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.

Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.

Acta Neuropathol. 2012 Jun;123(6):841-52. doi: 10.1007/s00401-011-0938-4. Epub 2012 Jan 15.

4.

The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.

Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, Sciuscio D, Burger R, Domany E, Stupp R, Hegi ME.

Neuro Oncol. 2011 Jul;13(7):736-47. doi: 10.1093/neuonc/nor036. Epub 2011 Jun 3.

5.

Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.

Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MC, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch A, Heppner FL, Yonekawa Y, Merlo A, Frei K, Mariani L, Hofer S.

Mol Cancer Ther. 2011 Jun;10(6):1102-12. doi: 10.1158/1535-7163.MCT-11-0048. Epub 2011 Apr 6.

6.

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

Sciuscio D, Diserens AC, van Dommelen K, Martinet D, Jones G, Janzer RC, Pollo C, Hamou MF, Kaina B, Stupp R, Levivier M, Hegi ME.

Clin Cancer Res. 2011 Jan 15;17(2):255-66. doi: 10.1158/1078-0432.CCR-10-1931. Epub 2010 Nov 19.

7.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.

J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.

PMID:
20439646
8.

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M, Flamion B, DiGuiseppi J, Bierau K, Hegi ME.

J Mol Diagn. 2008 Jul;10(4):332-7. doi: 10.2353/jmoldx.2008.070169. Epub 2008 Jun 13.

9.

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

Voelter V, Diserens AC, Moulin A, Nagel G, Yan P, Migliavacca E, Rimoldi D, Hamou MF, Kaina B, Leyvraz S, Hegi ME.

Int J Cancer. 2008 Sep 1;123(5):1215-8. doi: 10.1002/ijc.23632.

10.

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M.

Brain Pathol. 2008 Oct;18(4):520-32. doi: 10.1111/j.1750-3639.2008.00153.x. Epub 2008 Apr 8.

PMID:
18400046
11.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.

N Engl J Med. 2005 Mar 10;352(10):997-1003.

12.

INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma.

Lachat Y, Diserens AC, Nozaki M, Kobayashi H, Hamou MF, Godard S, De Tribolet N, Hegi ME.

Oncogene. 2004 Sep 9;23(41):6854-63. Erratum in: Oncogene. 2005 Feb 3;24(6):1128.

PMID:
15273738
13.

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R.

Clin Cancer Res. 2004 Mar 15;10(6):1871-4.

14.

Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.

Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF, Dietrich PY, Regli L, Janzer RC, Bucher P, Stupp R, de Tribolet N, Domany E, Hegi ME.

Cancer Res. 2003 Oct 15;63(20):6613-25.

15.

p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade.

Nozaki M, Tada M, Kashiwazaki H, Hamou MF, Diserens AC, Shinohe Y, Sawamura Y, Iwasaki Y, de Tribolet N, Hegi ME.

Brain Pathol. 2001 Jul;11(3):296-305.

PMID:
11414472
16.

Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.

Klein MA, RĂ¼edi D, Nozaki M, Dell EW, Diserens AC, Seelentag W, Janzer RC, Aguzzi A, Hegi ME.

Oncogene. 2000 Nov 9;19(47):5329-37.

17.

The endothelin system in human glioblastoma.

Egidy G, Eberl LP, Valdenaire O, Irmler M, Majdi R, Diserens AC, Fontana A, Janzer RC, Pinet F, Juillerat-Jeanneret L.

Lab Invest. 2000 Nov;80(11):1681-9.

18.

Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells.

Tenan M, Fulci G, Albertoni M, Diserens AC, Hamou MF, El Atifi-Borel M, Feige JJ, Pepper MS, Van Meir EG.

J Exp Med. 2000 May 15;191(10):1789-98.

19.

Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.

Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG.

Brain Pathol. 1999 Jul;9(3):469-79.

PMID:
10416987
20.

Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma.

Desbaillets I, Diserens AC, de Tribolet N, Hamou MF, Van Meir EG.

Oncogene. 1999 Feb 18;18(7):1447-56.

21.
22.

Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells.

Van Meir EG, Roemer K, Diserens AC, Kikuchi T, Rempel SA, Haas M, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK.

Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1008-12.

23.

Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro.

Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, Van Meir EG.

Int J Cancer. 1994 Jul 15;58(2):240-7.

PMID:
7517920
24.
25.

Production of interleukin-1 receptor antagonist by human glioblastoma cells in vitro and in vivo.

Tada M, Diserens AC, Desbaillets I, Jaufeerally R, Hamou MF, de Tribolet N.

J Neuroimmunol. 1994 Mar;50(2):187-94.

PMID:
8120140
26.

Analysis of the p53 gene and its expression in human glioblastoma cells.

Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK.

Cancer Res. 1994 Feb 1;54(3):649-52.

27.

[Overexpression of p53 protein in gliomas].

Kikuchi T, Diserens AC, Hamou MF, de Tribolet N, van Meir E.

No Shinkei Geka. 1994 Feb;22(2):125-9. Japanese.

PMID:
8115006
28.

Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas.

Li H, Hamou MF, de Tribolet N, Jaufeerally R, Hofmann M, Diserens AC, Van Meir EG.

Cancer Res. 1993 Nov 15;53(22):5345-9. Erratum in: Cancer Res 1994 Feb 1;54(3):859.

29.

Human glioblastoma cells release interleukin 6 in vivo and in vitro.

Van Meir E, Sawamura Y, Diserens AC, Hamou MF, de Tribolet N.

Cancer Res. 1990 Oct 15;50(20):6683-8.

30.
31.

Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.

Monod L, Diserens AC, Jongeneel CV, Carrel S, Ronco P, Verroust P, de Tribolet N.

Int J Cancer. 1989 Nov 15;44(5):948-51.

PMID:
2531122
32.

Effects of recombinant human tumor necrosis factor-alpha on the surface phenotype and the growth of human malignant glioma cell lines.

Zuber P, Accolla RS, Carrel S, Diserens AC, de Tribolet N.

Int J Cancer. 1988 Nov 15;42(5):780-6.

PMID:
3141300
33.

Heterogeneity of the induction of HLA-DR expression by human immune interferon on glioma cell lines and their clones.

Piguet V, Carrel S, Diserens AC, Mach JP, de Tribolet N.

J Natl Cancer Inst. 1986 Feb;76(2):223-8.

PMID:
3080635
34.

Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens.

de Muralt B, de Tribolet N, Diserens AC, Stavrou D, Mach JP, Carrel S.

Eur J Cancer Clin Oncol. 1985 Feb;21(2):207-16.

PMID:
2985398
35.

The immunobiology of human gliomas.

Piguet V, Diserens AC, Carrel S, Mach JP, de Tribolet N.

Springer Semin Immunopathol. 1985;8(1-2):111-27. Review. No abstract available.

PMID:
3890235
36.

Characterization of four human malignant glioma cell lines.

Studer A, de Tribolet N, Diserens AC, Gaide AC, Matthieu JM, Carrel S, Stavrou D.

Acta Neuropathol. 1985;66(3):208-17.

PMID:
2990147
37.

Reactivity of antiglioma monoclonal antibodies for a large panel of cultured gliomas and other neuroectoderm derived tumors.

de Muralt B, de Tribolet N, Diserens AC, Carrel S, Mach JP.

Anticancer Res. 1983 Jan-Feb;3(1):1-6.

PMID:
6830147
38.

Characterization of a rabbit anti-human malignant glioma antiserum.

Schnegg JF, de Tribolet N, Diserens AC, Martin-Achard A, Carrel S.

Int J Cancer. 1981 Sep 15;28(3):265-9. No abstract available.

PMID:
7319673
39.

Human glioma-associated antigens detected by monoclonal antibodies.

Schnegg JF, Diserens AC, Carrel S, Accolla RS, de Tribolet N.

Cancer Res. 1981 Mar;41(3):1209-13.

40.

Characterization of an established human malignant glioma cell line: LN-18.

Diserens AC, de Tribolet N, Martin-Achard A, Gaide AC, Schnegg JF, Carrel S.

Acta Neuropathol. 1981;53(1):21-8.

PMID:
7211194
41.

Evaluation of the humoral response of glioma patients to a possible common tumor-associated antigen(s).

Martin-Achard A, Diserens AC, de Tribolet N, Carrel S.

Int J Cancer. 1980 Feb 15;25(2):219-24.

PMID:
7390650
42.

Evaluation of the humoral response of meningioma patients to possible common tumour-associated antigens.

Mottet S, Martin-Achard A, de Tribolet N, Diserens AC.

Acta Neurochir (Wien). 1980;52(1-2):19-25.

PMID:
7376941
43.

[Central nervous system tumor tissue culture, part II: Mesodermic tumors, ectodermic tumors, neurinomas, metastasis].

de Tribolet N, Martin-Achard A, Diserens AC, Schnegg JF, Zander E.

Schweiz Arch Neurol Neurochir Psychiatr. 1980;126(1):5-15. French.

PMID:
7191141
44.

[Cultures of tissue from central nervous system tumors. Part 1. Neuroglial tumors].

de Tribolet N, Martin-Achard A, Diserens AC, Schnegg JF, Zander E.

Schweiz Arch Neurol Neurochir Psychiatr. 1979;125(1):59-71. French.

PMID:
545689
45.

[Anti-tumor antibodies in the blood of patients with gliomas].

Martin-Achard A, Diserens AC, de Tribolet N, Zander E, Carrel S.

Schweiz Med Wochenschr. 1978 Jun 24;108(25):959-62. French.

PMID:
663586
46.

Personal noise dosimetry in refinery and chemical plants.

Diserens AH.

J Occup Med. 1974 Apr;16(4):255-7. No abstract available.

PMID:
4819915
47.

A five-year review of a mercury control program.

Diserens AH.

Am Ind Hyg Assoc J. 1965 Mar-Apr;26(2):117-21. No abstract available.

PMID:
5828112

Supplemental Content

Loading ...
Support Center